Regina M. Paglia - 17 Jun 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Chief Human Resources Officer
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 17 Jun 2021
Net transactions value: -$153,563
Form type: 4
Filing time: 22 Jun 2021, 16:14:27 UTC
Previous filing: 17 Jun 2021
Next filing: 24 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$60,306	+4,664	+1734%	$12.93	4,933	17 Jun 2021	Direct
transaction	DRNA	Common Stock	Options Exercise	$96,200	+4,000	+81%	$24.05	8,933	17 Jun 2021	Direct
transaction	DRNA	Common Stock	Sale	$310,068	-8,664	-97%	$35.79	269	17 Jun 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-4,664	-4.5%	$0.000000	98,750	17 Jun 2021	Common Stock	4,664	$12.93	Direct	F3
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-4,000	-6.5%	$0.000000	57,500	17 Jun 2021	Common Stock	4,000	$24.05	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person sold an aggregate of 8,664 shares of Common Stock on June 17, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 3.51% of 246,488 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6950 to $35.8750, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3	The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
F4	The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.